ATAI LIFE SCIENCES BV

NASDAQ: ATAI (Atai Beckley N.V)

Kemas kini terakhir: 26 Nov, 4:29PM

3.75

-0.01 (-0.27%)

Penutupan Terdahulu 3.76
Buka 3.77
Jumlah Dagangan 2,263,388
Purata Dagangan (3B) 5,763,606
Modal Pasaran 1,361,964,544
Harga / Jualan (P/S) 252.78
Harga / Buku (P/B) 9.23
Julat 52 Minggu
1.15 (-69%) — 6.75 (80%)
Tarikh Pendapatan 12 Nov 2025
Margin Operasi (TTM) -1,239.23%
EPS Cair (TTM) -0.910
Pertumbuhan Hasil Suku Tahunan (YOY) -54.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 19.02%
Nisbah Semasa (MRQ) 4.07
Aliran Tunai Operasi (OCF TTM) -77.70 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -47.04 M
Pulangan Atas Aset (ROA TTM) -26.04%
Pulangan Atas Ekuiti (ROE TTM) -79.43%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Atai Beckley N.V Menurun Menaik

AISkor Stockmoo

0.4
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.0
Purata 0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ATAI 1 B - - 9.23
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 7.78%
% Dimiliki oleh Institusi 31.48%

Pemilikan

Nama Tarikh Syer Dipegang
Ally Bridge Group (Ny) Llc 30 Sep 2025 2,287,005
Brown University 30 Sep 2025 718,500
Julat 52 Minggu
1.15 (-69%) — 6.75 (80%)
Julat Harga Sasaran
12.00 (220%) — 15.00 (300%)
Tinggi 15.00 (HC Wainwright & Co., 300.00%) Beli
Median 14.00 (273.33%)
Rendah 12.00 (Needham, 220.00%) Beli
Purata 13.67 (264.53%)
Jumlah 3 Beli
Harga Purata @ Panggilan 5.55
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Canaccord Genuity 22 Oct 2025 14.00 (273.33%) Beli 5.64
Needham 13 Oct 2025 12.00 (220.00%) Beli 5.40
HC Wainwright & Co. 23 Sep 2025 15.00 (300.00%) Beli 5.61

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
19 Nov 2025 Pengumuman Enhanced Fortifies Executive Leadership Team & Board of Directors
13 Nov 2025 Pengumuman AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
12 Nov 2025 Pengumuman AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
10 Nov 2025 Pengumuman AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
05 Nov 2025 Pengumuman atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
20 Oct 2025 Pengumuman atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
16 Oct 2025 Pengumuman atai Life Sciences Announces Pricing of Public Offering of Common Shares
16 Oct 2025 Pengumuman atai Life Sciences Announces Proposed Public Offering of Common Shares
16 Oct 2025 Pengumuman atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
23 Sep 2025 Pengumuman atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
18 Sep 2025 Pengumuman atai Life Sciences Awarded Grant from the National Institutes of Health
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda